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Background: A systematic review, with or without a meta-analysis, should be undertaken to determine if the
research question of interest has already been answered before a new trial begins. There has been limited research
on how systematic reviews are used within the design of new trials, the aims of this study were to investigate how
systematic reviews of earlier trials are used in the planning and design of new randomised trials.
Methods: Documentation from the application process for all randomised trials funded by the National Institute for
Health Research Health Technology Assessment (NIHR HTA) between 2006 and 2008 were obtained. This included
the: commissioning brief (if appropriate), outline application, minutes of the Board meeting in which the outline
application was discussed, full application, detailed project description, referee comments, investigator response to
referee comments, Board minutes on the full application and the trial protocol. Data were extracted on references
to systematic reviews and how any such reviews had been used in the planning and design of the trial.
Results: 50 randomised trials were funded by NIHR HTA during this period and documentation was available for 48
of these. The cohort was predominately individually randomised parallel trials aiming to detect superiority between
two treatments for a single primary outcome. 37 trials (77.1%) referenced a systematic review within the application
and 20 of these (i.e. 41.7% of the total) used information contained in the systematic review in the design or
planning of the new trial. The main areas in which systematic reviews were used were in the selection or definition
of an outcome to be measured in the trial (7 of 37, 18.9%), the sample size calculation (7, 18.9%), the duration of
follow up (8, 21.6%) and the approach to describing adverse events (9, 24.3%). Boards did not comment on the
presence/absence or use of systematic reviews in any application.
Conclusions: Systematic reviews were referenced in most funded applications but just over half of these used the
review to inform the design. There is an expectation from funders that applicants will use a systematic review to
justify the need for a new trial but no expectation regarding further use of a systematic review to aid planning and
design of the trial. Guidelines for applicants and funders should be developed to promote the use of systematic
reviews in the design and planning of randomised trials, to optimise delivery of new studies informed by the most
up-to-date evidence base and to minimise waste in research.
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Table 1 Application characteristics
Number of trials
(n=48), n (%)
Type of trial Parallel 42 (87.5)
Cluster 5 (10.4)
Factorial 1 (2.1)
Nature Superiority 37 (77.1)
Non-inferiority 7 (14.6)
Equivalence 4 (8.3)




Number of trial arms 2 37 (77.1)
3 9 (18.8)
4 2 (4.2)
Median Sample size (range) 583 (172 to 20,000)
Jones et al. BMC Medical Research Methodology 2013, 13:50 Page 2 of 6
http://www.biomedcentral.com/1471-2288/13/50Background
The value of systematic reviews to identify areas requir-
ing further health care research is well known [1], and a
systematic review, with or without a meta-analysis,
should be undertaken to determine if the research ques-
tion of interest has already been answered before a new
trial begins [2].
To help researchers use findings from systematic re-
views in the design of new trials, a four stage framework
has been suggested [3]: step one is to outline the popula-
tions, interventions, comparators, outcomes, timing and
setting of the new trial; step two is to identify a relevant,
valid and current systematic review; step three is to use
the systematic review to inform the proposed trial; and
step four is to summarise the implications for the new
trial. However, there has been limited research on how
systematic reviews are used within the design of new trials,
with research to date focused on what is reported when
the findings of a trial are published [4-6]. Given the poten-
tial for poorly planned trials to waste limited resources
and introduce unnecessary delays in resolving the uncer-
tainty that prompted the trial then every effort should be
made to learn from the experience of relevant trials.
When publishing the results of a new trial the emphasis
is on the ethical, scientific and environmental justification
for conducting the trial and on setting its results in the
context of the existing evidence base. It is therefore likely
that trial publications may under report the ways in which
systematic reviews were used to inform design. To over-
come this limitation, we investigated a cohort of funding
applications for randomised trials to identify where existing
research is used not only to justify the need for conducting
a trial but also to inform the design of the trial.
Methods
We examined a cohort of randomised trials that had
received funding from the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA)
programme in the United Kingdom, in 2006, 2007 and
2008 due to the availability of the information that was
required for the project. The NIHR HTA funding process
(http://www.hta.ac.uk [accessed 30 April 2012]) involves
several stages and all relevant documentation was pro-
vided: the commissioning brief (if appropriate), outline ap-
plication, minutes of the Board meeting in which the
outline application was discussed, full application, detailed
project description, referee comments, investigator re-
sponse to referee comments, Board minutes on the full
application and the trial protocol.
A data extraction form was designed and piloted. Data
were extracted to characterise the cohort and to categorise
ways in which systematic reviews were used to inform the
design of the proposed trial including the justification of
treatment comparison, choice of frequency or dose,selection of (or definition of) an outcome, recruitment
and consent rates, sample size (margin of equivalence or
non-inferiority, size of difference, control group event rate,
measure of variability and loss to follow up adjustment),
length of follow-up, withdrawals, missing data or adverse
events. Data on each application were extracted independ-
ently by two reviewers (APJ and EC). Disagreements were
resolved by discussion or consultation with a third person
(CG).
All results are presented in tables with number of occur-
rences and percentages; no formal statistical testing was
undertaken. A confidentiality agreement with the NIHR
HTA programme was signed prior to receiving the docu-
mentation for the cohort therefore the raw data cannot be
made publicly available. Text extracts from the applica-
tions have been anonymised by removal of treatment or
condition identifiers. Deleted text is denoted by [. . .] and
[words] denotes addition of words or replaced words to
aid understanding while maintaining anonymity.Results
We received documentation for the applications of 50
subsequently funded randomised trials, but there was in-
sufficient documentation to consider two of these for in-
clusion in this study.
The characteristics of the 48 applications in the cohort
are described in Table 1. The cohort was predominately in-
dividually randomised parallel trials aiming to detect super-
iority between two treatments for a single primary outcome
with a median total sample size of 583. Table 2 describes
the clinical area that the application was based in, with
mental health and cancer having the most applications.
Table 2 Clinical application of applications
Clinical area Number of applications
N=48
Alcohol consumption 1




Falls in the elderly 1










Table 3 The use of systematic reviews in trial design
Area of use Number of applications (%)
(n=37)
Justification of treatment comparisons 6 (16.2)
Choice of frequency/dose 2 (5.4)
Selection or definition of outcome 7 (18.9)
Recruitment and consent 2 (5.4)
Estimating the difference to detect or
margin of equivalence
6 (16.2)
Estimating the control group event rate 3 (8.1)
Inform standard deviation 1 (2.7)
Duration of follow up 8 (21.6)
Withdrawal rate 1 (2.7)
Adverse events 9 (24.3)
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and 37 applications (79%) referenced a systematic review
within the application for funding. Twenty of these 37 ap-
plications (54.1%) reported the use of the systematic re-
view in the design of the RCT, the other 17 did not.
Applications that did not reference a systematic review
Seven of the eleven applications that did not reference a
systematic review stated that there had been no previous
trials either of the interventions to be compared or within
the relevant population, with one of these explicitly stating
an absence of a systematic review. However, it was not
clear within these seven cases that the absence of relevant
studies was based on a robust search strategy. One of the
other applications was for a pilot study implying the ab-
sence of previous relevant trials, one discussed an on-
going study, and two discussed relevant randomised trials
but with no clear indication of how these had been identi-
fied. For all eleven of these applications, the absence of a
systematic review was not referred to in the Board mi-
nutes or the referees’ comments.
Applications that did reference a systematic review
Of the 37 applications that did reference a systematic review,
15 referenced more than one systematic review, with 65 sys-
tematic reviews referenced in total across the applications.
Twenty three (35%) of these 65 systematic reviews had been
published in the Cochrane Database of Systematic Reviews
and 42 (65%) had been published in another journal. Twenty
(54.1% of the 37) of the applications used the systematic re-
view in some way in the design or planning of the new trial(Table 3) with the median (range) number of ways a review
was used in each of these 20 applications being 2 (1 to 5).
Justification of treatment comparisons
Six applications used systematic reviews in the justifica-
tion of the treatment group (see Additional file 1).
Five of these six applications justified the proposed treat-
ments based on effectiveness shown in a systematic review.
In response to a referee’s comment to ‘make a stronger
case for this RCT’ and justify the chosen treatment re-
gimes, applicants made greater use of evidence from a
Cochrane Review initially referenced in their application
(application 5). In another application (application 6), a
referee requested justification for participant inclusion cri-
teria and the applicants responded highlighting data from
a trial which was included within the systematic review.
Choice of frequency/dose
Two applications used a systematic review in the choice
of dose of the intervention (see Additional file 2). One
application used essentially the same dose as one of the
trials in the systematic review but stated the frequency
of administration had not been previously tested in a
trial (application 7). The second application stated that
the systematic review showed that dosing regimens var-
ied widely and the dose range that was chosen for the
new trial was based on one within that range that had
shown clinical benefit (application 8).
Selection or definition of an outcome
Seven applications used evidence from systematic re-
views to justify the outcome in the proposed trial (see
Additional file 3).
In five of the seven applications the systematic review had
specifically stated the outcome or outcomes that should be
measured in future research and this was used as justifica-
tion for choosing a specific outcome in the applications.
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identify previous commonly used measures of health-
related quality of life, but the application did not intend
to use those identified within the systematic review and
provided justification for this (application 10).
One application used the systematic review to inform
the definition of a secondary outcome of the study and
the cut off for the outcome in the application was based
on evidence from the systematic review (application 13).
Recruitment and consent
Two applications used information presented in system-
atic reviews to aid planning of patient recruitment (see
Additional file 4).
Only one application explicitly discussed consent rates
as observed within trials included within the systematic
review. This application justified the consent rate as-
sumed in the application based on relevant previous tri-
als in the systematic review (application 2).
The second application used poor recruitment rates
reported in previous relevant trials included in a systematic
review to determine site selection criteria (application 10).
Sample size calculation
Estimating the difference to detect or the margin
of equivalence
Five of the 37 (13.5%) applications that aimed to detect a
difference referenced a systematic review when defining
the size of the difference that they wished to detect in their
trial. The applications used the actual difference from the
meta-analysis or the applicants used a figure from one of
the trials in the systematic review (see Additional file 5).
In one (9.1%) of the eleven equivalence/non-inferiority
trials, a systematic review was referenced when defining the
margin of equivalence. The applicants stated that they used
the effect estimate from the systematic review as the mar-
gin of equivalence. However, we were unable to determine
which review this data came from when we checked the
four reviews referenced in the application (application 4).
Estimating the control group event rate
Three applications used a systematic review to estimate
the control group event rate (see Additional file 6). The
figures that were used in the sample size calculations were
taken directly from the systematic review in two examples
(application 7 and 9) and, in the third example, the figures
were very similar to those in the review (application 14).
Inform standard deviation
One application referenced a systematic review to justify
the standard deviation that they had used in the sample
size calculation; the standard deviation that was used
was the mid-point of the standard deviations of the two
trials included in the review (see Additional file 7).Duration of follow up
Eight applications referred to a systematic review in
order to justify the duration of follow up during a trial
(see Additional file 8).
Based on the conclusions within systematic reviews, six
applications called for long term follow up, rather than short
term follow up and two applications stated that the system-
atic review supported establishing evidence for both short
term and long term effects (applications 16 and 20). We
found no definitions of ‘long term’ or ‘short term’ within the
recommendations of any of these systematic reviews.
Withdrawal rate
One application increased their sample size by a fixed
amount based on estimates of the withdrawal rate from
trials in the systematic review (see Additional file 9).
Adverse events
Nine applications provided information on adverse events
that had been reported from a systematic review (see
Additional file 10). In two applications, the number of
events and rates were described in detail (applications 8
and 19). In six applications it was reported on whether the
treatment(s) had shown any increase or decrease in ad-
verse events and in one application (application 20) it was
reported that the systematic review had recommended in-
vestigation possible adverse effects of the drug.
Discussion
This study has investigated how systematic reviews were
used in the planning and design of randomised trials that
have been funded by the NIHR HTA programme during
the period of 2006 to 2008. The results show that system-
atic reviews are referenced in the majority (77.1%) of suc-
cessful applications for funding of randomised trials by the
HTA, but 17 of these 37 applications (45.9%) did not re-
port the use of the systematic review in the design of the
trial. The main areas in which systematic reviews were
used in the planning of the new trial were in the selection
or definition of the outcome, the sample size calculation
and the duration of follow up. Descriptions of adverse
events in previous studies were referenced, but it was un-
clear whether they were then used to inform the study ad-
verse event planning.
There is limited evidence on how systematic reviews are
used in the planning and design of randomised trials. This
study is unique both in terms of the number of trials in-
cluded and the information that was reviewed, because all
documentation from the application process was made
available to us. One potential weakness of this study was
that we were not permitted to have access to unsuccessful
applications, meaning that we are not able to assess if there
is a difference in the use of systematic reviews between
those applications that were successful in gaining funding
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UK funding body which funds trials across a range of health
care settings and conditions. We are not aware of any rea-
sons why the results from the study will not be generalis-
able to other funding agencies and to other countries.
Previous research has shown that authors of new
randomised trials were often unaware of relevant reviews
when designing trials. For example, Cooper et al. [6] found
that 13 (55%) of 24 authors of new published trials in-
cluded in an updated Cochrane Review were unaware of
the review version available at the time of study design and
eight (33%) used the systematic review in study design.
Goudie et al. [4] looked at how trials were designed and
reported in the context of previous evidence in two
journals (JAMA and the Archives of Internal Medicine)
and reported that previous trial results were consulted dur-
ing the design of 10 trials (37%). This phenomenon of re-
searchers not consulting previous evidence was highlighted
by Clarke et al. who stated that most researchers ‘do not
seem to have considered systematic reviews when design-
ing their trial’ [5]. Limitations on the available resources to
conduct clinical trials, both in patient populations and
costs, would suggest that every effort should be made to
learn from the experience of relevant trials.
There are over 2500 systematic reviews published
every year (a quarter of which are on the Cochrane
Database of Systematic Reviews [7]). It is essential that
researchers applying for funding for new trials search
the literature to identify relevant systematic reviews and
use that information not only to justify the need for the
new trial but also to design and plan that trial [8]. There
are also calls for authors of reviews to be more specific
about what further research is needed [1,9].
It is important that funders of trials ensure that appli-
cants have used the most up-to-date and relevant evi-
dence in designing a trial and that information on how
the evidence has been used is described in the applica-
tion. We recommend that applicants stating absence of
previously conducted relevant trials support this state-
ment by providing a systematic search strategy, and that
funding bodies ask applicants to justify the trial design
in each of the areas listed within Table 2. These are de-
tails that could be requested by the CONSORT state-
ment in the reporting of a trial [10]. The potential for
systematic reviews to impact on trial design could be
maximised if authors of systematic reviews are more
specific about what further research is needed.
The PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) checklist can be included
when reporting a systematic review and item #26 does
state that authors should ‘Provide a general interpretation
of the results in the context of other evidence, and impli-
cations for future research’ [11], however we believe there
should be a minimum set of recommendations within theimplications for future research and that these should in-
clude recommendations for the types of intervention, par-
ticipants and outcomes to be studied.
Future research
Our study has highlighted that the majority of new NIHR
HTA-funded trials referenced systematic reviews during
the application process, to justify the new trial but that
even among those that did reference a systematic review,
almost half did not use the review to inform the trial de-
sign. We plan to investigate guidelines from organisations
that fund randomised trials to gather details of the infor-
mation that is requested when funding applications are
made. The use of systematic reviews within Value of Infor-
mation (VOI) analyses, which aim to provide an objective
method for informing the decision of which trials to fund
and how best to design them, should also be explored.
Conclusions
Systematic reviews are frequently referenced in the major-
ity of successful applications for funding but underutilised
in the planning of that research. There is an expectation
from funders that applicants will use a systematic review
to justify the need for a new trial but no clear expectations
regarding further use of a systematic review to aid plan-
ning and design of the trial. Guidelines for applicants and
funders should be developed to promote the use of sys-
tematic reviews in the design and planning of randomised
trials, to optimise delivery of new studies informed by the
most up-to-date evidence base and to minimise waste in
research. Systematic review authors could maximise the
impact on trial design by reporting the factors that are im-
portant in planning a future trial.
Additional files
Additional file 1: How an application used a systematic review for
the justification of treatment comparisons.
Additional file 2: How an application used a systematic review for
the choice of the frequency/dose.
Additional file 3: How an application used a systematic review for
the selection or definition of an outcome.
Additional file 4: How an application used a systematic review for
recruitment and consent.
Additional file 5: How an application used a systematic review in
estimating the difference to detect or margin of equivalence.
Additional file 6: How an application used a systematic review to
estimate the control group event rate.
Additional file 7: How an application used a systematic review to
inform the standard deviation.
Additional file 8: How an application used a systematic review to
justify the duration of follow up.
Additional file 9: How an application used a systematic review to
estimate withdrawal rate.
Additional file 10: How an application used a systematic review to
describe adverse events.
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